Drugs / PEGAPAMODUTIDE
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02188303 | Jul → Dec 2014 | — | OPKO Health, Inc. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02119819 | Apr 2014 → Aug 2015 | type 2 diabetes mellitus | OPKO Health, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEGAPAMODUTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990012 ↗ |
| Known as | LY2944876 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02188303 ↗ |
| Known as | Pegapamodutida | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990012 ↗ |
| Action | Activate | “Glucagon-like peptide 1 receptor agonist” CHEMBL3990012 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL3990012 ↗ |
| Route | Subcutaneous | “Administered SC” NCT02119819 ↗ |
| Target | GLP1R | “Glucagon-like peptide 1 receptor agonist” CHEMBL3990012 ↗ |